Evidence map›Paper›PMID 42321206›Full record

ArticleNature communications2026

Soluble CD95L triggers Caspase-10-driven reactive oxygen species production in neutrophils and aggravates anti-neutrophil cytoplasmic antibody-vasculitis.

Andréa Boizard-Moracchini, Dhouha Msalbi, Sarah Huot-Marchand, Layla Haymour, Eden Lebrault, John Tchen, Titia Jekel, Gaël Galli, Benoît Brilland, Nathalie Mérillon and 18 more

Registry-linked trialAbstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03698071 (Soluble CD95 Ligand Role in the Pathophysiology of ANCA Associated Vasculitis), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03698071 nacompletednot on this map

Soluble CD95 Ligand Role in the Pathophysiology of ANCA Associated Vasculitis

TypeinterventionalSponsorUniversity Hospital, BordeauxRan2018 to 2024Enrolled48ConditionsANCA Associated VasculitisArmsblood sample, urine sample
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Andréa Boizard-Moracchini *University of Bordeaux, CNRS, ImmunoConcEpT, UMR, Bordeaux, France.
Dhouha Msalbi *INSERM U1262, UMR 7276, CRIBL, University of Limoges, Limoges, France.
Sarah Huot-Marchand *University of Bordeaux, CNRS, ImmunoConcEpT, UMR, Bordeaux, France.
Layla HaymourINSERM U1262, UMR 7276, CRIBL, University of Limoges, Limoges, France.
Eden LebraultINSERM U1262, UMR 7276, CRIBL, University of Limoges, Limoges, France.
John TchenUniversity of Bordeaux, CNRS, ImmunoConcEpT, UMR, Bordeaux, France.
Titia JekelUniversity of Bordeaux, CNRS, ImmunoConcEpT, UMR, Bordeaux, France.
Gaël GalliUniversity of Bordeaux, CNRS, ImmunoConcEpT, UMR, Bordeaux, France.ORCID http://orcid.org/0009-0009-9336-0059
Benoît BrillandService de Néphrologie-Dialyse-Transplantation, University of Angers, CHU Angers, Angers, France.
Nathalie MérillonUniversity of Bordeaux, CNRS, ImmunoConcEpT, UMR, Bordeaux, France.
Coralie JosensiUniversity of Bordeaux, CNRS, ImmunoConcEpT, UMR, Bordeaux, France.
Clément LozanoUniversity of Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SPI, Bagnols-sur-Cèze, France.
Juliana MazarsINSERM U1262, UMR 7276, CRIBL, University of Limoges, Limoges, France.
Matthieu DouardUniversity of Bordeaux, INSERM U1045, Centre de Recherche Cardio-Thoracique de Bordeaux, Pessac, France.
Yannick DangerEFS Rennes, Rue Pierre Jean Gineste, Rennes, Cedex, France.
Franck VéritéEFS Rennes, Rue Pierre Jean Gineste, Rennes, Cedex, France.
Thomas BarnetcheCentre national de référence maladie auto-immune et systémique rares Est/Sud-Ouest (RESO), Bordeaux University Hospital, Bordeaux, France.
Estibaliz LazaroCentre national de référence maladie auto-immune et systémique rares Est/Sud-Ouest (RESO), Bordeaux University Hospital, Bordeaux, France.ORCID http://orcid.org/0000-0002-4206-7399
Pierre DuffauInternal Medicine Department, Saint André, Bordeaux University Hospital, Bordeaux, France.
Pierre PfirmannNephrology Department, Bordeaux University Hospital, Bordeaux, France.
Aude Magerus-ChatinetINSERM U1163. IMAGINE - Institut des Maladies Génétiques, Paris, France.ORCID http://orcid.org/0000-0001-7365-699X
Mickael JeanUniversity of Rennes, CNRS, ISCR - UMR 6226, Rennes, France.ORCID http://orcid.org/0000-0001-8885-8586
Jean-François AugustoService de Néphrologie-Dialyse-Transplantation, University of Angers, CHU Angers, Angers, France.
Jean ArmengaudUniversity of Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SPI, Bagnols-sur-Cèze, France.ORCID http://orcid.org/0000-0003-1589-445X
Christophe RichezUniversity of Bordeaux, CNRS, ImmunoConcEpT, UMR, Bordeaux, France.ORCID http://orcid.org/0000-0002-3029-8739
Pierre VacherUniversity of Bordeaux, INSERM U1045, Centre de Recherche Cardio-Thoracique de Bordeaux, Pessac, France.ORCID http://orcid.org/0000-0003-3503-7981
Patrick Legembre *INSERM U1262, UMR 7276, CRIBL, University of Limoges, Limoges, France. patrick.legembre@inserm.fr.ORCID http://orcid.org/0000-0001-6649-8049
Patrick Blanco *University of Bordeaux, CNRS, ImmunoConcEpT, UMR, Bordeaux, France. patrick.blanco@chu-bordeaux.fr.ORCID http://orcid.org/0000-0002-5374-3639

Funding

Agence Nationale de la Recherche (French National Research Agency) ANR-22-CE15-0038-02Agence Nationale de la Recherche (French National Research Agency) ANR-24-CE18-2934
6 · The paper itself

Abstract

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a severe autoimmune disease that lacks effective targeted therapies. T cell and neutrophil activation are associated with tissue lesions in ANCA-associated vasculitis responsible for the necrotizing vasculitis of small blood vessels. Although the aberrant release of reactive oxygen species (ROS) by neutrophils contribute to the disruption of the endothelial barrier, the underlying molecular mechanisms of this oxidative burst remain unclear. Here, we observe that blood vessels in the inflamed organs of patients with AAV express CD95L, which is cleaved by metalloproteases to release soluble CD95L (sCD95L). sCD95L stimulates ROS production in AAV neutrophils via a caspase-driven mechanism. Proteomic analysis reveals that the deubiquitinase OTULIN is a caspase substrate in sCD95L-exposed neutrophils. Caspase-10 cleaves OTULIN after its aspartates at positions 31 and 54 to unleash the activity of E3 ligase complex LUBAC and trigger mitochondrion-dependent ROS production in AAV neutrophils. Inhibition of the CD95-mediated non-apoptotic signaling abrogates ROS production in AAV neutrophils and alleviates clinical symptoms in AAV and crescentic glomerulonephritis mouse models, indicating that CD95 and CD95L represent attractive molecular targets for patients with AAV.

Indexed as

Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisFas Ligand ProteinNeutrophilsReactive Oxygen SpeciesAnimalsEndopeptidasesfas ReceptorFemaleHumansMaleMiceMice, Inbred C57BLEndopeptidasesFas Ligand Proteinfas ReceptorReactive Oxygen Species

Identifiers

PMID42321206
PMCPMC13434393

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.